BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ho JJC, Navarro M, Sawyer K, Elfanagely Y, Moss SF. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2022;117:1221-30. [PMID: 35509128 DOI: 10.14309/ajg.0000000000001828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Gobert AP, Asim M, Smith TM, Williams KJ, Barry DP, Allaman MM, McNamara KM, Hawkins CV, Delgado AG, Blanca Piazuelo M, Rathmacher JA, Wilson KT. The nutraceutical electrophile scavenger 2-hydroxybenzylamine (2-HOBA) attenuates gastric cancer development caused by Helicobacter pylori. Biomed Pharmacother 2023;158:114092. [PMID: 36493697 DOI: 10.1016/j.biopha.2022.114092] [Reference Citation Analysis]
2 Yunusa I, Love BL. Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs. Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States. Am J Gastroenterol 2023. [PMID: 36693030 DOI: 10.14309/ajg.0000000000002146] [Reference Citation Analysis]
3 Liu L, Nahata MC. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. Ann Pharmacother 2023;:10600280221149708. [PMID: 36688309 DOI: 10.1177/10600280221149708] [Reference Citation Analysis]
4 Zhou BG, Mei YZ, Zhang M, Jiang X, Li YY, Ding YB. High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Therap Adv Gastroenterol 2023;16:17562848221147756. [PMID: 36644129 DOI: 10.1177/17562848221147756] [Reference Citation Analysis]
5 Argueta EA, Ho JJC, Elfanagely Y, D'Agata E, Moss SF. Clinical Implication of Drug Resistance for H. pylori Management. Antibiotics (Basel) 2022;11. [PMID: 36551341 DOI: 10.3390/antibiotics11121684] [Reference Citation Analysis]
6 Aumpan N, Mahachai V, Vilaichone RK. Management of Helicobacter pylori infection. JGH Open 2023;7:3-15. [PMID: 36660052 DOI: 10.1002/jgh3.12843] [Reference Citation Analysis]
7 Bordin DS, Livzan MA, Osipenko MF, Mozgovoy SI, Andreyev DN, Maev IV. The key statements of the Maastricht VI consensus. jour 2022. [DOI: 10.31146/1682-8658-ecg-205-9-5-21] [Reference Citation Analysis]
8 Jia X, Huang Q, Lin M, Chu Y, Shi Z, Zhang X, Ye H. Revealing the novel effect of Jinghua Weikang capsule against the antibiotic resistance of Helicobacter pylori. Front Microbiol 2022;13:962354. [DOI: 10.3389/fmicb.2022.962354] [Reference Citation Analysis]
9 Shatila M, Thomas AS. Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection. JCM 2022;11:5086. [DOI: 10.3390/jcm11175086] [Reference Citation Analysis]